9ISI image
Deposition Date 2024-07-17
Release Date 2025-04-23
Last Version Date 2025-07-16
Entry Detail
PDB ID:
9ISI
Title:
Structure of human C3aR in apo state
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Escherichia coli (Taxon ID: 562)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.56 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:C3a anaphylatoxin chemotactic receptor,Soluble cytochrome b562
Gene (Uniprot):cybC, C3AR1
Mutations:M1012W/H1107I
Chain IDs:A (auth: B)
Chain Length:501
Number of Molecules:1
Biological Source:Homo sapiens, Escherichia coli
Ligand Molecules
Primary Citation
Structural insights into small-molecule agonist recognition and activation of complement receptor C3aR.
Embo J. 44 2803 2826 (2025)
PMID: 40195498 DOI: 10.1038/s44318-025-00429-w

Abstact

The complement system plays crucial roles in innate immunity and inflammatory responses. The anaphylatoxin C3a mediates pro-inflammatory and chemotactic functions through the G protein-coupled receptor C3aR. While the active structure of the C3a-C3aR-Gi complex has been determined, the inactive conformation and activation mechanism of C3aR remain elusive. Here we report the cryo-EM structure of ligand-free, G protein-free C3aR, providing insights into its inactive conformation. In addition, we determine the structures of C3aR in complex with the synthetic small-molecule agonist JR14a in two distinct conformational states: a G protein-free intermediate, and a fully active Gi-bound state. The structure of the active JR14a-bound C3aR reveals that JR14a engages in highly conserved interactions with C3aR, similar to the binding of the C-terminal pentapeptide of C3a, along with JR14a-specific interactions. Structural comparison of C3aR in the apo, intermediate, and fully active states provides novel insights into the conformational landscape and activation mechanism of C3aR and defines a molecular basis explaining its high basal activity. Our results may aid in the rational design of therapeutics targeting complement-related inflammatory disorders.

Legend

Protein

Chemical

Disease

Primary Citation of related structures